LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Начало・Списък с акции・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

21.75 1.97

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.24

Максимум

21.91

Ключови измерители
By Trading Economics
Приходи	-270M 3.6M
Продажби	-16M 268M
P/E Средно за сектора	9.548 50.102
EPS	0.02
Марж на печалбата	1.357
Служители	796
EBITDA	-31M -4.6M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+52.57% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-186M 3.6B
Предишно отваряне	19.78
Предишно затваряне	21.75

Настроения в новините

By Acuity

25%

75%

55 / 344 Класиране в Healthcare

ACADIA Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.05.2026 г., 22:47 ч. UTC

Печалби

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28.05.2026 г., 20:45 ч. UTC

Печалби

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28.05.2026 г., 23:31 ч. UTC

Пазарно говорене

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28.05.2026 г., 22:37 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

M&A-Related Insurance Payments In North America Rise -- Market Talk

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28.05.2026 г., 21:12 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28.05.2026 г., 21:00 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28.05.2026 г., 20:57 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:55 ч. UTC

Печалби

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

28.05.2026 г., 20:48 ч. UTC

Горещи акции

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28.05.2026 г., 20:34 ч. UTC

Печалби

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28.05.2026 г., 20:31 ч. UTC

Печалби

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28.05.2026 г., 20:28 ч. UTC

Печалби

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28.05.2026 г., 20:26 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Membership Fees $1.37B

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Net Sales $69.15B

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Same-Store Sales Up 9.8% >COST

Сравнение с други в отрасъла

Ценова промяна

ACADIA Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

52.57% нагоре

12-месечна прогноза

Среден 32.33 USD 52.57%

Висок 38 USD

Нисък 23 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за ACADIA Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на ACADIA Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

55 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.